Phio Pharmaceuticals完成首个商业化cGMP批次生产
Phio Pharmaceuticals Corp. (0001533040) (Filer)
Phio Pharmaceuticals Corp. 于2026年10月13日宣布成功完成首个商业化cGMP批次的PH-762药物物质生产，该批次为公司计划于2027年第一季度启动的IIb期临床试验提供支持。相关公告作为8-K文件提交至SEC。
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): October 13, 2026
PHIO PHARMACEUTICALS CORP.
(Exact name of registrant as specified in its charter)
|
Delaware |
001-36304 |
45-3215903 |
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
|
411 Swedeland Road, Suite 23-1080 |
|
|
King of Prussia, PA |
19406 |
|
(Address of principal executive offices) |
(Zip Code) |
Registrant’s telephone number, including area code: (610) 947-0251
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class: |
Trading Symbol(s): |
Name of each exchange on which registered: |
||
|
Common Stock, par value $0.0001 per share |
PHIO |
The Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On October 13, 2026, the Company issued a press release announcing the successful completion of its first commercial-scale cGMP Batch of PH-762 drug substance, a key operational milestone that supports the planned initiation of the Company's Phase 2b clinical trial in the first quarter of 2027.
The full text of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No. |
Description |
|
|
99.1 |
||
|
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
PHIO PHARMACEUTICALS CORP. |
||
|
Date: October 13, 2026 |
By: |
/s/ Robert J. Bitterman |
|
Robert J. Bitterman President & Chief Executive Officer |
||
3
来源：SEC EDGAR · 本站存档